Aktienanalyse zu SI-BONE Inc (SIBN)SIBNSI-BONE Inc

SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

SI-BONE Inc is a good buy right now due to its recent financial improvements, including a 15.2% year-over-year revenue growth to $56 million in Q2 2026 and a significant reduction in net loss by 33.6% to $4.08 million. The current price of $19.21 is below the analyst price target of $25, suggesting strong upside potential. However, the main risk is the negative EPS of -0.09, which indicates ongoing losses.

4 analysts cover SIBN: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 25.17.